Document is current
Any future updates will be listed below
-
Authors
,
Machado, Alejandra
Ferreira, Daniel http://orcid.org/0000-0001-9522-4338
Grothe, Michel J.
Eyjolfsdottir, Helga
Almqvist, Per M.
Cavallin, Lena
Lind, Göran
Linderoth, Bengt
Seiger, Åke
Teipel, Stefan
Wahlberg, Lars U.
Wahlund, Lars-Olof
Westman, Eric
Eriksdotter, Maria
-
Funding
Funding for this research was provided by:
Swedish Research council (2016-02317)
Swedish Foundation for Strategic Research
Regional agreement on medical training and clinical research (ALF) between Stockholm County Council and Karolinska Institutet
Strategic Research Programme in Neuroscience at Karolinska Institutet
Swedish Alzheimer foundation
The Swedish Brain foundation
- License Information
-
More Information
Article History
Received: 12 September 2019
Accepted: 22 April 2020
First Online: 6 May 2020
Ethics approval and consent to participate
: The study protocol and informed consent form were reviewed and approved by the institutional review board of each center. For the NGF, the Swedish Medical Products Agency and the Regional Human Ethics Committee of Stockholm approved the study (Dnr 2007/986-31/3). The patients and their caregivers gave us written informed consent prior to study inclusion.
: Informed consent for the publication of data was obtained from the participants or their caregivers.
: Lars Wahlberg is an owner and employee of Gloriana Therapeutics, which developed the NGF secreting device. All the other authors declared no conflicts of interest.
